文献速递免疫规划

FSME-IMMUN 在儿童青少年及年轻成人中的抗体持久性与加强应答

Seropersistence and booster response following vaccination with FSME-IMMUN in children, adolescents, and young adults.
PubMed 文献 · Vaccine · 2019-03-27

该研究为 4 期前瞻性开放标签随访研究,评估 3 剂基础免疫后 2–5 年及首次加强后 3–10 年的抗体持久性,并观察加强应答。结果显示基础免疫后 5 年 NT 血清阳性率为 84.9%,首次加强后 5 年 NT 为 99.4%、10 年为 90.3%;所有接受第二次加强者均出现强抗体应答,提示可将加强间隔延长至 10 年。

要点

  • 完成 3 剂基础免疫后 5 年 NT 血清阳性率 84.9%,ELISA 为 72.0%。
  • 首次加强后 5 年 NT 血清阳性率 99.4%,10 年为 90.3%。
  • 所有接受第二次加强者抗体均强应答,提示可延长加强间隔至 10 年。

核心结论

  • 3 剂基础免疫和首次加强后 TBEV 抗体可长期持久存在,受试者具备良好的免疫记忆应答。
  • 研究认为将 FSME-IMMUN 加强间隔延长至 3 剂基础免疫后最多 10 年似乎是有依据的。

研究设计与样本

  • 4 期前瞻性开放标签随访研究,全部受试者接种 FSME-IMMUN。
  • 3 剂基础免疫后随访 2–5 年;358 名受试者中 205 名(57%)接受首次加强,其中 179 名(87%)进入进一步 10 年随访。
  • 每年评估抗体持久性,滴度低于预设界值者接受加强,评估血清阳性率和几何平均倍数升高(GMFR)。

主要发现

  • 1–15 岁完成 3 剂基础免疫的儿童,第 3 剂后 5 年 NT 血清阳性率 84.9%、ELISA 72.0%。
  • 首次加强后 1 个月,NT 血清阳性率 100%、ELISA 98.5%,GMFR 为 3.7–11.4。
  • 首次加强后 5 年 NT 血清阳性率 99.4%、ELISA 97.5%;10 年 NT 90.3%、ELISA 87.7%。
  • 各年龄组血清阳性率存在差异,但接受第二次加强者(100%)均出现 TBEV 抗体的强劲升高。

关键数值与推荐

  • 3 剂基础免疫后 5 年:NT 血清阳性率 84.9%,ELISA 72.0%。
  • 首次加强后 1 个月:NT 血清阳性率 100%,ELISA 98.5%,GMFR 3.7–11.4。
  • 首次加强后 5 年:NT 99.4%,ELISA 97.5%;10 年:NT 90.3%,ELISA 87.7%。
  • 第二次加强后:100% 受试者抗体强劲升高。

临床怎么用

  • 完成 3 剂基础免疫后可按血清阳性率下降趋势评估个体加强时机。
  • 首次加强后抗体可持久 10 年,支持将加强间隔延长至基础免疫后最多 10 年。
  • 无论何时接受首次或第二次加强,均可获得良好免疫记忆应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tick-borne encephalitis (TBE) is a viral disease that can have a severe clinical course and considerable long-term morbidity. As no curative treatment exists, vaccination is the primary means of prevention. Long-term antibody seropersistence 2-5 years after the 3-dose primary immunization and 3-10 years after first booster was evaluated, as well as booster responses in children, adolescents and young adults. METHODS: Subjects who participated in these phase 4 prospective, open-label follow-up studies received all vaccinations with FSME-IMMUN. After 3-dose primary immunization, subjects were followed for 2-5 years. Overall, 205 out of 358 subjects (57%) received the first booster and 179 of these subjects (87%) enrolled in a further 10-year follow-up. Antibody seropersistence was assessed annually. Subjects with a TBE antibody titer below a pre-specified cut-off at the yearly blood draw received a booster. Seropositivity rates and geometric mean fold rises (GMFRs) were assessed. RESULTS: In children who received their 3-dose primary immunization between 1 and 15 years of age, the seropositivity rate 5 years after the 3rd dose was 84.9% by NT and 72.0% by ELISA. One month post-first booster, all subjects were seropositive by NT and 98.5% by ELISA. Response to first booster by GMFR ranged from 3.7 to 11.4. At 5 years post-first booster, seropositivity was 99.4% by NT and 97.5% by ELISA, and at 10 years, was 90.3% by NT and 87.7% by ELISA. Although seropositivity rates differed between age groups, all subjects (100%) who received a second booster responded with a robust increase of TBEV antibodies. DISCUSSION: Long-lasting seropersistence of TBEV antibodies after the 3-dose primary immunization and first booster was demonstrated as well as a competent immune memory response in those who received a first or second booster at any time during the 15-year follow-up. Therefore, an extension of FSME-IMMUN booster interval up to 10 years after the 3-dose primary immunization seems warranted. ClinicalTrials.gov Identifier: NCT00894686.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Poellabauer E, Angermayr R, Behre U, et al. Seropersistence and booster response following vaccination with FSME-IMMUN in children, adolescents, and young adults. Vaccine. 2019. PMID: 30928173. doi:10.1016/j.vaccine.2019.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。